Supernus Pharmaceuticals (SUPN) Earnings Date, Estimates & Call Transcripts $31.92 +0.08 (+0.25%) (As of 12:46 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 13EstimatedActual EPS (Aug. 6) $0.36 Missed By -$0.03 Consensus EPS (Aug. 6) $0.39 Conference Call TranscriptConference Call AudioEarnings Press ReleaseSEC 10-Q/10-K Filing Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueSUPN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.SUPN Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad True Gold RepublicCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. Supernus Pharmaceuticals Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:$1.53 EPSNext Year EPS Consensus Estimate: $1.35 EPSSUPN Earnings Date and InformationSupernus Pharmaceuticals last released its earnings results on August 6th, 2024. The specialty pharmaceutical company reported $0.36 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.39 by $0.03. The business earned $168.30 million during the quarter, compared to analyst estimates of $148.83 million. Its quarterly revenue was up 24.1% compared to the same quarter last year. Supernus Pharmaceuticals has generated ($0.29) earnings per share over the last year (($0.29) diluted earnings per share). Earnings for Supernus Pharmaceuticals are expected to decrease by -11.76% in the coming year, from $1.53 to $1.35 per share. Supernus Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 13th, 2024 based off prior year's report dates.Read More Supernus Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/13/2024(Estimated)------- 8/6/2024Q2 2024$0.39$0.36($0.03)$0.36$148.83 million$168.30 million 2/27/2024Q4 2023$0.41$0.02($0.39)$0.02$155.03 million$164.30 million 11/8/2023Q3 2023$0.13($0.29)($0.42)($0.29)$143.39 million$153.88 million 8/8/2023Q2 2023$0.23($0.02)($0.25)($0.02)$143.63 million$135.56 million 5/9/2023Q1 2023$0.12$0.29+$0.17$0.29$139.02 million$153.80 million 2/28/2023Q4 2022$0.73$0.43($0.30)$0.43$180.38 million$167.33 million Central Bank Abandons USD (Ad)Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide.11/8/2022Q3 2022$0.32$0.03($0.29)$0.03$173.22 million$177.35 million 8/4/2022Q2 2022$0.30$0.14($0.16)$0.14$164.23 million$170.10 million 5/9/2022Q1 2022$0.26$0.43+$0.17$0.43$150.47 million$152.50 million 4/13/2022Q4 2021-$0.04+$0.04$0.04-$159.05 million 11/3/2021Q3 2021$0.21$0.40+$0.19$0.40$141.32 million$148.46 million 8/4/2021Q2 2021$0.17$0.43+$0.26$0.43$135.50 million$141.33 million 5/5/2021Q1 2021$0.26$0.11($0.15)$0.11$131.77 million$130.93 million 2/25/2021Q4 2020$0.57$0.57-$0.57$145.52 million$143.56 million 11/3/2020Q3 2020$0.27$0.74+$0.47$0.74$130.76 million$155.10 million 8/18/2020Q2 2020$0.42$0.65+$0.23$0.65$126.70 million$126.73 million 5/5/2020Q1 2020$0.30$0.40+$0.10$0.40$84.01 million$94.98 million 2/25/2020Q4 2019$0.57$0.62+$0.05$0.62$107.27 million$100.45 million 11/5/2019Q3$0.59$0.54($0.05)$0.54$108.70 million$102.14 million Supernus Pharmaceuticals Earnings - Frequently Asked Questions When is Supernus Pharmaceuticals's earnings date? Supernus Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 13th, 2024 based off last year's report dates. Learn more on SUPN's earnings history. What guidance has Supernus Pharmaceuticals issued on next quarter's earnings? Supernus Pharmaceuticals updated its FY 2024 earnings guidance on Tuesday, August, 6th. The company issued revenue guidance of $600.0 million-$625.0 million, compared to the consensus revenue estimate of $600.1 million. Did Supernus Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Supernus Pharmaceuticals (NASDAQ:SUPN) missed the analysts' consensus estimate of $0.39 by $0.03 with a reported earnings per share (EPS) of $0.36. Learn more on analysts' earnings estimate vs. SUPN's actual earnings. How can I listen to Supernus Pharmaceuticals's earnings conference call? The conference call for Supernus Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Supernus Pharmaceuticals's conference call transcript? The conference call transcript for Supernus Pharmaceuticals's latest earnings report can be read online. Read Transcript How can I view Supernus Pharmaceuticals's earnings report? Supernus Pharmaceuticals's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Supernus Pharmaceuticals generate each year? Supernus Pharmaceuticals (NASDAQ:SUPN) has a recorded annual revenue of $607.52 million. How much profit does Supernus Pharmaceuticals generate each year? Supernus Pharmaceuticals (NASDAQ:SUPN) has a recorded net income of $1.32 million. SUPN has generated -$0.29 earnings per share over the last four quarters. What is Supernus Pharmaceuticals's EPS forecast for next year? Supernus Pharmaceuticals's earnings are expected to decrease from $1.53 per share to $1.35 per share in the next year, which is a -11.76% change. More Earnings Resources from MarketBeat Related Companies: KNSA Earnings Results OCUL Earnings Results ARQT Earnings Results INVA Earnings Results PHAT Earnings Results ORIC Earnings Results KPTI Earnings Results BTAI Earnings Results JAZZ Earnings Results PRGO Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit OutlookDon’t Count Out CrowdStrike Yet: Key Insights from Q2 Earnings This page (NASDAQ:SUPN) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absoluteDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Supernus Pharmaceuticals, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
